| Literature DB >> 18392848 |
Judith Boone1, Richard van Hillegersberg, Paul J van Diest, G Johan A Offerhaus, Inne H M Borel Rinkes, Fiebo J W Ten Kate.
Abstract
Tissue microarray (TMA) technology has been developed to facilitate high-throughput immunohistochemical and in situ hybridization analysis of tissues by inserting small tissue biopsy cores into a single paraffin block. Several studies have revealed novel prognostic biomarkers in esophageal squamous cell carcinoma (ESCC) by means of TMA technology, although this technique has not yet been validated for these tumors. Because representativeness of the donor tissue cores may be a disadvantage compared to full sections, the aim of this study was to assess if TMA technology provides representative immunohistochemical results in ESCC. A TMA was constructed containing triplicate cores of 108 formalin-fixed, paraffin-embedded squamous cell carcinomas of the esophagus. The agreement in the differentiation grade and immunohistochemical staining scores of CK5/6, CK14, E-cadherin, Ki-67, and p53 between TMA cores and a subset of 64 randomly selected donor paraffin blocks was determined using kappa statistics. The concurrence between TMA cores and donor blocks was moderate for Ki-67 (kappa = 0.42) and E-cadherin (kappa = 0.47), substantial for differentiation grade (kappa = 0.65) and CK14 (kappa = 0.71), and almost perfect for p53 (kappa = 0.86) and CK5/6 (kappa = 0.93). TMA technology appears to be a valid method for immunohistochemical analysis of molecular markers in ESCC provided that the staining pattern in the tumor is homogeneous.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18392848 PMCID: PMC2329733 DOI: 10.1007/s00428-008-0602-0
Source DB: PubMed Journal: Virchows Arch ISSN: 0945-6317 Impact factor: 4.064
Specification of antibodies used and details of tissue processing
| Primary antibody | Staining pattern | Sourcea | Clone and code | Antigen retrieval | Dilution | Incubation time (min/room temperature) | Detectionb | Positive control | Procedure |
|---|---|---|---|---|---|---|---|---|---|
| CK5/6 | Cytoplasmic | Chemicon | D5/16 B4 | EDTA pH 9.0 | 1:3,000 | 60 | Strept ABC | Breast | Autostainer |
| CK14 | Cytoplasmic | Neomarkers | LL002 | EDTA pH 9.0 | 1:400 | 60 | Powervision | Breast | Autostainer |
| E-cadherin | Membranous | Zymed | 4A2C7 | Citrate autoclave pH 6.0 | 1:200 | 60 | Powervision | Breast | Autostainer |
| MIB-1 (Ki-67) | Nuclear | Dako | M7240 | Citrate pH 6.0 | 1:100 | 60 | Strept ABC | Tonsil | Autostainer |
| p53 | Nuclear | Biogenex | BP53-12 | Citrate pH 6.0 | 1:200 | 60 | Strept ABC | Serous adenocarcinoma of the endometrium | Autostainer |
aBiogenex, San Ramon, CA, USA; Chemicon, Chemicon International, Temecula, CA, USA; Dako, DakoCytomation, Glostrup, Denmark; Neomarkers, Fremont, USA; Zymed, Zymed Laboratories, San Francisco, CA, USA.
bStrept ABC is biotinylated horse–antimouse Vector BA-2000, diluted 1:500 in PBS, followed by streptavidin–biotin complex, diluted 1:1,000. Powervision ready to use (Poly-HRP-antiMs/Rb/RtIgG biotin-free; ImmunoVision Technologies, Norwell, CA, USA).
Overview of the amount of cores that were evaluable, absent or contained too little tumor in all 108 cases and in the 64 randomly selected cases on the TMA slides
| H&E | CK5/6 | CK14 | E-cadherin | Ki-67 | p53 | Median | |
|---|---|---|---|---|---|---|---|
| Total TMA cases ( | |||||||
| No. of evaluable cores | 293 | 309 | 294 | 306 | 293 | 295 | 295 |
| Percentage | 90 | 95 | 91 | 94 | 90 | 91 | 91 |
| No. of absent cores | 20 | 7 | 22 | 9 | 22 | 22 | 21 |
| Percentage | 6 | 2 | 7 | 3 | 7 | 7 | 6 |
| No. of cores without tumor | 11 | 8 | 8 | 9 | 9 | 7 | 9 |
| Percentage | 4 | 3 | 3 | 3 | 3 | 2 | 3 |
| Randomly selected TMA cases ( | |||||||
| No. of evaluable cores | 176 | 187 | 176 | 185 | 176 | 176 | 176 |
| Percentage | 92 | 97 | 92 | 96 | 92 | 92 | 92 |
| No. of absent cores | 13 | 3 | 13 | 4 | 13 | 13 | 13 |
| Percentage | 7 | 2 | 7 | 2 | 7 | 7 | 7 |
| No. of cores without tumor | 3 | 2 | 3 | 3 | 3 | 3 | 3 |
| Percentage | 2 | 1 | 2 | 2 | 2 | 2 | 2 |
H&E: hematoxylin and eosin
Agreement in the degree of differentiation between TMA cores and full sections
| Full section | ||||||
|---|---|---|---|---|---|---|
| G1 | G2 | G3 | Total | |||
| TMA | G1 | 2 | 3 | 0 | 5 | |
| G2 | 2 | 21 | 2 | 25 | ||
| G3 | 0 | 7 | 26 | 33 | ||
| Total | 4 | 31 | 28 | 63 | 0.65 | |
G1: well-differentiated, G2: moderately differentiated, G3: poorly differentiated
Fig. 1Example of strong CK5/6 staining in TMA cores and the corresponding full section. a Three TMA cores representing one tumor; magnification ×20. b Enlargement of the middle TMA core depicted in a; magnification ×100. c Part of the slide of the donor block of the same tumor; magnification ×100
Agreement in immunohistochemical scores between TMA cores and full slides stained for CK5/6 and CK14
| Full sections | ||||||
|---|---|---|---|---|---|---|
| <10% | 10–80% | ≥80% | Total | |||
| TMAs | CK5/6 | |||||
| <10% | 1 | 1 | 0 | 2 | ||
| 10–80% | 0 | 4 | 0 | 4 | ||
| ≥80% | 0 | 0 | 58 | 58 | ||
| Total | 1 | 5 | 58 | 64 | 0.93 | |
| CK14 | ||||||
| <10% | 5 | 2 | 1 | 8 | ||
| 10–80% | 0 | 11 | 2 | 13 | ||
| ≥80% | 0 | 4 | 34 | 38 | ||
| Total | 5 | 17 | 37 | 59 | 0.71 | |
Agreement in immunohistochemical scores between TMA cores and full slides stained for E-cadherin
| Full sections | |||||
|---|---|---|---|---|---|
| E-cadherin | <50% | ≥50% | Total | ||
| TMA | <50% | 22 | 17 | 39 | |
| ≥50% | 1 | 24 | 25 | ||
| Total | 23 | 41 | 64 | 0.47 | |
Agreement in immunohistochemical scores between TMA cores and full slides stained for Ki-67 and p53
| Full sections | ||||||
|---|---|---|---|---|---|---|
| <10% | 10–50% | ≥50% | Total | |||
| TMAs | Ki-67 | |||||
| <10% | 2 | 1 | 0 | 3 | ||
| 10–50% | 3 | 42 | 3 | 48 | ||
| ≥50% | 0 | 6 | 4 | 10 | ||
| Total | 5 | 49 | 7 | 61 | 0.42 | |
| p53 | ||||||
| <10% | 19 | 3 | 0 | 22 | ||
| 10–50% | 0 | 1 | 2 | 3 | ||
| ≥50% | 0 | 3 | 35 | 38 | ||
| Total | 19 | 7 | 37 | 63 | 0.86 | |
Fig. 2Representative example of E-cadherin staining in TMA cores and the corresponding full section. a Three TMA cores representing one tumor; magnification ×20. b Enlargement of the right TMA core depicted in a; magnification ×100. c Part of the slide of the donor block of the same tumor; magnification ×100
Fig. 3Representative example of p53 staining in TMA cores and the corresponding full section. a Three TMA cores representing one tumor; magnification ×20. b Enlargement of the left TMA core depicted in a; magnification ×100. c Part of the slide of the donor block of the same tumor; magnification ×100